A sponge-like gold nanoparticle platform could deliver faster, more accurate, and less invasive ovarian cancer diagnostics.
For University of Queensland (UQ) PhD researcher Javeria Bashir, materials science has always been more than a theoretical curiosity – it’s a means to solve real-world medical challenges. Her current research applies advanced nanomaterials to one of the toughest problems in women’s health: detecting ovarian cancer early. Motivated by personal experiences witnessing loved ones through the trauma of invasive biopsies and late-stage cancer diagnoses, Bashir’s work seeks to create diagnostic tools that are gentle, precise, and accessible.
Ovarian cancer, often called the “silent killer”, rarely produces clear symptoms in its early stages. Currently, there is no reliable screening test capable of consistently identifying it before it progresses. Biopsies remain invasive and stressful, and the lack of accurate, non-invasive alternatives delays crucial treatment. Bashir’s innovation aims to fill that gap by detecting cancer markers from small, easily collected bodily fluids such as urine, saliva, or blood – allowing women to be triaged earlier and more accurately.
Javeria and her team’s vision is to reimagine the diagnostic pathway. If successful, this innovation could reduce the need for invasive biopsies, speed up referrals for women at genuine risk, and give clinicians clearer, data-driven guidance – ultimately improving survival outcomes.
To eventually translate this innovation toward clinical use, Ms Bashir said extensive experimental optimization and clinical validation are still required before moving into large-scale manufacturing or commercialization. She hopes that, as the research matures, collaborations with industry and clinical partners could help scale production and integrate the system into diagnostic devices in the future.
“Our current focus is on strengthening the experimental foundation and validating the technology with larger patient cohorts,” she said. “In the long term, collaborations with industry will be essential for taking this kind of nanoparticle-based platform from academic research to practical diagnostic applications.”
The science behind the gold
At the heart of Bashir’s work lies Surface-Enhanced Raman Scattering (SERS) – a light-based technique capable of detecting weak chemical signatures from biological samples. The innovation comes from her specially engineered mesoporous, or sponge-like, gold nanoparticles that amplify these signals to unprecedented levels. When a laser interacts with biomarkers near the nanoparticles, the light is scattered in unique “fingerprints” that reveal the presence of disease.
The porous architecture of these nanoparticles gives them a much larger surface area than commercially available nonporous gold particles. This design creates countless tiny pores that act as hotspots, intensifying the light and generating stronger signals. The result is a sensor platform capable of detecting even the faintest cancer biomarkers.
“Think of them like little antennas,” Bashir explained. “They capture and amplify light at the nanoscale, strengthening weak signals from cancer markers. This improves sensitivity – the ability to detect cancer – and specificity, helps to distinguish between cancerous and non-cancerous signals.”
Working in collaboration with experts from UQ’s School of Mechanical and Mining Engineering, the Australian Institute for Bioengineering and Nanotechnology (AIBN), UQ Centre for Clinical Research (UQCCR) and the Centre for Extracellular Vesicle Nanomedicine, Bashir was able to fine-tune the nanostructure to maximise diagnostic performance.
Compact, accessible, and scalable
One of the most promising aspects of the technology is its accessibility. Rather than relying on bulky laboratory systems, the diagnostic process uses a simple sample tube and a handheld Raman spectrophotometer. The spectrophotometer is a portable device that reads the light signals generated by the gold nanoparticles. The simplicity of the setup makes it suitable for point-of-care testing, even in resource-limited or remote settings.
This approach means healthcare professionals could potentially screen for ovarian cancer in local clinics without needing specialised equipment or highly trained technicians. Bashir’s platform has already demonstrated 82 per cent sensitivity in confirming ovarian cancer and 98 per cent specificity in ruling it out. These results exceed many existing screening tools.
“Instead of needing large, expensive lab equipment, the test is quick, user-friendly, and doesn’t require highly trained staff – which means it could be used in local clinics, not just specialist hospitals,” she said.
Such accessibility could be life-changing for women in under-resourced areas who often face delays in diagnosis simply due to a lack of testing infrastructure.
From proof-of-concept to clinical translation
Bashir’s proof-of-concept studies have demonstrated that SERS-based detection can identify ovarian cancer biomarkers with high sensitivity and specificity using extracellular vesicles isolated from patient plasma samples. Although not yet compared head-to-head with current clinical blood tests, the early findings suggest a leap forward in non-invasive cancer detection.
The next steps are rigorous. To bring the technology into hospitals and clinics, Bashir and her collaborators will need to scale up testing with larger patient cohorts, conduct clinical trials, and meet regulatory standards. This is where collaboration becomes crucial.
Her research brings together the Mater Research Institute and the Oregon Health & Science University (OHSU) – two key partners that have provided ethically approved patient samples and clinical expertise. These collaborations ensure that the diagnostic design aligns with real clinical needs and patient realities.
“Collaboration has been central to this research,” Bashir said. “The OHSU team provided well-characterised plasma samples from women with confirmed ovarian cancer, benign conditions, and healthy controls, while Mater researchers offered clinical insights to help align our diagnostic approach with real patient needs. Together, we’re bridging the gap between materials science and medicine.”
Beyond its technical sophistication, Bashir’s project carries profound implications for healthcare equity. Ovarian cancer outcomes vary across regions, with rural and low-resource communities often suffering higher mortality rates due to late diagnosis. The portability, simplicity, and affordability of her device could change that dynamic.
“Women in remote or under-resourced areas often face delays in diagnosis simply because advanced testing facilities aren’t available,” Bashir noted. “Our technology is designed to be fast, portable, affordable, and could be used outside major hospitals – even in community health settings – helping reduce health inequity and potentially saving more lives through earlier detection.”
By removing the need for invasive biopsies or complex imaging, the technology offers a gentler and faster route to diagnosis. It’s a step towards a healthcare model where precision tools are not limited to large institutions but can be accessed wherever they’re needed most.
While the current focus is on ovarian cancer, the platform’s potential extends much further. The same nanoparticle-based approach could be adapted to detect biomarkers for other cancers or even infectious diseases – simply by changing the targeted biomarkers. This flexibility could open new frontiers in personalised and preventive medicine.
“The platform is versatile,” she said. “By changing the biomarker we target, the same technology can be used for other cancers or even infectious diseases. That’s the exciting part of nanotechnology – it’s not limited to one condition.”
Reimagining personalised medicine
Looking ahead, Bashir envisions a healthcare landscape transformed by nanotechnology and biomedical engineering. Instead of a one-size-fits-all model, she imagines diagnostic devices capable of giving every patient accurate, real-time information about their health. This will, in turn, empower clinicians to tailor treatments accordingly.
Her work, published in the journal Small, represents a crucial step toward that vision. By combining material science and biomedical engineering, Bashir’s sponge-like gold nanoparticles are a symbol of how technology can make healthcare more humane, equitable, and effective.
“My vision is for healthcare where a simple, portable device can give every patient accurate information about their condition – empowering doctors to tailor treatment and improving outcomes worldwide,” she said.
.jpg)
